The potential of exosomes derived from chronic myelogenous leukaemia cells as a biomarker

Ka Won Kang; Jik Han Jung; Woojune Hur; Jaena Park; Hyunku Shin; Byeonghyeon Choi; Hyesun Jeong; Dae Sik Kim; Eun Sang Yu; Se Ryeon Lee; Hwa Jung Sung; Seok Jin Kim; Chul Won Choi; Hyun Koo Kim; Sunghoi Hong; Ji Ho Park; Yeonho Choi; Yong Park; Byung Soo Kim

doi:10.21873/anticanres.12679

The potential of exosomes derived from chronic myelogenous leukaemia cells as a biomarker

Ka Won Kang, Jik Han Jung, Woojune Hur, Jaena Park, Hyunku Shin, Byeonghyeon Choi, Hyesun Jeong, Dae Sik Kim, Eun Sang Yu, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, Chul Won Choi, Hyun Koo Kim, Sunghoi Hong, Ji Ho Park, Yeonho Choi, Yong Park, Byung Soo Kim

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Background/Aim: Exosomes, derived from chronic myelogenous leukaemia (CML) cells, can be used as biomarkers and new targets for the detection of the BCR-ABL transcript. This study aimed to identify these possibilities. Materials and Methods: Human CML cell line-derived exosomes and CML-patients-derived exosomes were isolated with a size-exclusion chromatography column and ExoQuick™ exosome precipitation solution, respectively. Isolated exosomes were analysed by nested PCR to detect the BCR-ABL transcript. Results: Exosomes derived from the two human CML cell lines yielded a 250-bp band. RNA sequence analysis revealed 99% sequence homology with the partial mRNA for the human BCR-ABL chimeric protein. This ~250-bp band was also observed in the exosomes derived from patients with CML. However, only patients at the blast and accelerated phases showed the exosomal BCR-ABL transcript. Conclusion: CML-derived exosomes could act as novel targets for the detection of the BCR-ABL transcript.

Original language	English
Pages (from-to)	3935-3942
Number of pages	8
Journal	Anticancer research
Volume	38
Issue number	7
DOIs	https://doi.org/10.21873/anticanres.12679
Publication status	Published - 2018 Jul

Keywords

BCR-ABL
Biomarker
Chronic myelogenous leukaemia
Exosome

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.12679

Cite this

Kang, K. W., Jung, J. H., Hur, W., Park, J., Shin, H., Choi, B., Jeong, H., Kim, D. S., Yu, E. S., Lee, S. R., Sung, H. J., Kim, S. J., Choi, C. W., Kim, H. K., Hong, S., Park, J. H., Choi, Y., Park, Y., & Kim, B. S. (2018). The potential of exosomes derived from chronic myelogenous leukaemia cells as a biomarker. Anticancer research, 38(7), 3935-3942. https://doi.org/10.21873/anticanres.12679

@article{f02ae0a259184fc5b7a7c508d0eb3249,

title = "The potential of exosomes derived from chronic myelogenous leukaemia cells as a biomarker",

abstract = "Background/Aim: Exosomes, derived from chronic myelogenous leukaemia (CML) cells, can be used as biomarkers and new targets for the detection of the BCR-ABL transcript. This study aimed to identify these possibilities. Materials and Methods: Human CML cell line-derived exosomes and CML-patients-derived exosomes were isolated with a size-exclusion chromatography column and ExoQuick{\texttrademark} exosome precipitation solution, respectively. Isolated exosomes were analysed by nested PCR to detect the BCR-ABL transcript. Results: Exosomes derived from the two human CML cell lines yielded a 250-bp band. RNA sequence analysis revealed 99% sequence homology with the partial mRNA for the human BCR-ABL chimeric protein. This ~250-bp band was also observed in the exosomes derived from patients with CML. However, only patients at the blast and accelerated phases showed the exosomal BCR-ABL transcript. Conclusion: CML-derived exosomes could act as novel targets for the detection of the BCR-ABL transcript.",

keywords = "BCR-ABL, Biomarker, Chronic myelogenous leukaemia, Exosome",

author = "Kang, {Ka Won} and Jung, {Jik Han} and Woojune Hur and Jaena Park and Hyunku Shin and Byeonghyeon Choi and Hyesun Jeong and Kim, {Dae Sik} and Yu, {Eun Sang} and Lee, {Se Ryeon} and Sung, {Hwa Jung} and Kim, {Seok Jin} and Choi, {Chul Won} and Kim, {Hyun Koo} and Sunghoi Hong and Park, {Ji Ho} and Yeonho Choi and Yong Park and Kim, {Byung Soo}",

note = "Funding Information: This research was supported by a Grant of the Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HR14C0007), and by a grant of the Korea University Medical Center and Anam Hospital, Seoul, Republic of Korea (grant number: K1620041) and K1426441. Publisher Copyright: {\textcopyright} 2018 International Institute of Anticancer Research. All rights reserved.",

year = "2018",

month = jul,

doi = "10.21873/anticanres.12679",

language = "English",

volume = "38",

pages = "3935--3942",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "7",

}

TY - JOUR

T1 - The potential of exosomes derived from chronic myelogenous leukaemia cells as a biomarker

AU - Kang, Ka Won

AU - Jung, Jik Han

AU - Hur, Woojune

AU - Park, Jaena

AU - Shin, Hyunku

AU - Choi, Byeonghyeon

AU - Jeong, Hyesun

AU - Kim, Dae Sik

AU - Yu, Eun Sang

AU - Lee, Se Ryeon

AU - Sung, Hwa Jung

AU - Kim, Seok Jin

AU - Choi, Chul Won

AU - Kim, Hyun Koo

AU - Hong, Sunghoi

AU - Park, Ji Ho

AU - Choi, Yeonho

AU - Park, Yong

AU - Kim, Byung Soo

N1 - Funding Information: This research was supported by a Grant of the Korea Health Technology R & D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HR14C0007), and by a grant of the Korea University Medical Center and Anam Hospital, Seoul, Republic of Korea (grant number: K1620041) and K1426441. Publisher Copyright: © 2018 International Institute of Anticancer Research. All rights reserved.

PY - 2018/7

Y1 - 2018/7

N2 - Background/Aim: Exosomes, derived from chronic myelogenous leukaemia (CML) cells, can be used as biomarkers and new targets for the detection of the BCR-ABL transcript. This study aimed to identify these possibilities. Materials and Methods: Human CML cell line-derived exosomes and CML-patients-derived exosomes were isolated with a size-exclusion chromatography column and ExoQuick™ exosome precipitation solution, respectively. Isolated exosomes were analysed by nested PCR to detect the BCR-ABL transcript. Results: Exosomes derived from the two human CML cell lines yielded a 250-bp band. RNA sequence analysis revealed 99% sequence homology with the partial mRNA for the human BCR-ABL chimeric protein. This ~250-bp band was also observed in the exosomes derived from patients with CML. However, only patients at the blast and accelerated phases showed the exosomal BCR-ABL transcript. Conclusion: CML-derived exosomes could act as novel targets for the detection of the BCR-ABL transcript.

AB - Background/Aim: Exosomes, derived from chronic myelogenous leukaemia (CML) cells, can be used as biomarkers and new targets for the detection of the BCR-ABL transcript. This study aimed to identify these possibilities. Materials and Methods: Human CML cell line-derived exosomes and CML-patients-derived exosomes were isolated with a size-exclusion chromatography column and ExoQuick™ exosome precipitation solution, respectively. Isolated exosomes were analysed by nested PCR to detect the BCR-ABL transcript. Results: Exosomes derived from the two human CML cell lines yielded a 250-bp band. RNA sequence analysis revealed 99% sequence homology with the partial mRNA for the human BCR-ABL chimeric protein. This ~250-bp band was also observed in the exosomes derived from patients with CML. However, only patients at the blast and accelerated phases showed the exosomal BCR-ABL transcript. Conclusion: CML-derived exosomes could act as novel targets for the detection of the BCR-ABL transcript.

KW - BCR-ABL

KW - Biomarker

KW - Chronic myelogenous leukaemia

KW - Exosome

UR - http://www.scopus.com/inward/record.url?scp=85049772803&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12679

DO - 10.21873/anticanres.12679

M3 - Article

C2 - 29970515

AN - SCOPUS:85049772803

SN - 0250-7005

VL - 38

SP - 3935

EP - 3942

JO - Anticancer Research

JF - Anticancer Research

IS - 7

ER -

The potential of exosomes derived from chronic myelogenous leukaemia cells as a biomarker

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this